Treść książki
Przejdź do opcji czytnikaPrzejdź do nawigacjiPrzejdź do informacjiPrzejdź do stopki
2.CabezasM.,BurgraaffB.,KlopB.:Dyslipidemiasinclinicalpractice.Clin.
Chim.Acta2018;487:117-125.
3.ChyzhykV.,BrownA.S.:Familialchylomicronemiasyndrome:ararebutdevastat-
ingautosomatrecesivedisordercharacterizedbyrefractoryhypertriglyceridemiaand
reccurentpancreatitis.TrendsinCardiovasc.Med.2020;30:80-85.
4.LaufsU.,ParhoferK.G.,GinsbergH.N.,HegeleR.A.:Clinicalreviewontri-
glycerides.Eur.HeartJ.2020;41:99-109.
5.MachF.,BaigentC.,CatapanoA.L.iwsp.:2019ESC/EASGuidelinesforthe
managementofdyslipidaemias:lipidmodifcationtoreducecardiovascularrisk.The
TaskForceforthemanagementofdyslipidaemiasoftheEuropeanSocietyofCar-
diology(ESC)andEuropeanAtherosclerosisSociety(EAS).Eur.HeartJ.2019;
41:111-188.
6.MoulinP
.,DufourR.,AvernaM.iwsp.:Identifcationanddiagnosisofpatients
withfamilialchylomicronemiasyndrome(FCS):Expertpanelrecommendationsand
proposalofan“FCSscore”.Atherosclerosis2018;275:265-272.
7.NordestgaardB.G.,LangloisM.R.,LangstedA.iwsp.:Quantifyingatherogenic
lipoproteinsforlipid-loweringstrategies:Consensus-basedrecommendationsfrom
EASandEFLM.Atherosclerosis2019.
8.NordestgaardB.G.,LangstedA.,MoraS.iwsp.:Fastingisnotroutinelyre-
quiredfordeterminationoflipidprofle:clinicalandlaboratoryimplicationsincluding
flaggingatdesirableconcentrationcut-points-ajointconsensusstatementfromthe
EuropeanAtherosclerosisSocietyandEuropeanFederationofClinicalChemistryand
LaboratoryMedicine.Eur.HeartJ.2016;37:1944-1958.
9.SnidermanA.D.,deGraffJ.,ThanassoulisG.iwsp.:ThespectrumoftypeIII
hyperlipoproteinemia.J.Clin.Lipidol.2018;12:1383-1389.
10.SolnicaB.,SygitowiczG.,SitkiewiczD.iwsp.:2020GuidelinesofthePolish
SocietyofLaboratoryDiagnostics(PSLD)andthePolishLipidAssociation(PoLA)
onlaboratorydiagnosticsoflipidmetabolismdisorders.Arch.Med.Sci.2020;
16:237-252.
11.StroesE.,MoulinP.,ParhoferK.G.iwsp.:Diagnosticalgoritmforfamilial
chylomicronemiasyndrome.Atherosclerosissuppl.2017;23:1-7.
12.TaghizadehE.,EsfehaniR.J.,ParizadehS.M.iwsp.:Familialcombinedhy-
perlipidemia:Anoverviewoftheunderlyingmolecularmechanismsandtherapeutic
strategies.Criticalreview.IUBMBLife2019;71:1221-1229.
44
50Diagnostykazaburzeńlipidowych
